Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.32 |
| ▸ | LCK | P06239 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24067435 | 0.81 | PDE5A (0.41) | PDE5ALCKEGFRMEN1KMT2A | |
| SCHEMBL26237948 | 0.69 | PDE5A (0.38) | PDE5AEGFRMEN1KMT2AALDH1A1 | |
| SCHEMBL25670574 | 0.69 | ACHE (0.38) | PDE5AEGFRMEN1KMT2AALDH1A1 | |
| SCHEMBL12775449 | 0.68 | PDE5A (0.62) | PDE5A | |
| SCHEMBL10203311 | 0.66 | EGFR (0.50) | LCKEGFR | |
| SCHEMBL20813807 | 0.64 | PDE5A (0.42) | PDE5ALCKEGFRMEN1KMT2A | |
| SCHEMBL14671423 | 0.63 | POLB (0.50) | PDE5ALCKEGFRMEN1KMT2A | |
| SCHEMBL20813448 | 0.63 | PDE5A (0.41) | PDE5ALCKEGFRMEN1KMT2A | |
| SCHEMBL25670576 | 0.62 | HTR1A (0.46) | PDE5AEGFRMEN1KMT2A | |
| SCHEMBL26238161 | 0.61 | FGFR2 (0.40) | PDE5AEGFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | PDE5A 494/4885LCK 1000/4885EGFR 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.